Glaucoma surgery aims to lower intraocular pressure (IOP), which is the fluid pressure inside the eye, to stop damage to the optic nerve. When medical therapies like eye drops or laser treatment fail to control pressure, surgery creates alternative drainage routes for aqueous humor, the fluid inside the front chamber of the eye. Surgical categories range from traditional full-thickness or guarded filtration operations, such as trabeculectomy and glaucoma drainage devices, to newer micro-invasive glaucoma surgery (MIGS) options that offer faster recovery with modest pressure reduction.

Glaucoma surgery is performed under local anesthesia with mild conscious sedation. For trabeculectomy, the surgeon creates a small flap in the sclera (white wall of the eye) beneath the upper eyelid. A small opening is made into the anterior chamber to allow fluid to escape under the scleral flap into a small reservoir called a filtration bleb beneath the conjunctiva. Anti-scarring medications like mitomycin C are applied to prevent the tissue from healing shut. For micro-invasive glaucoma surgery (MIGS), tiny micro-stents or catheters are inserted through small corneal incisions into Schlemm's canal or the suprachoroidal space under microscopic visualization, facilitating natural fluid outflow.

Evidence-Based Clinical Benefits

• Lowering Intraocular Pressure: Surgery significantly reduces intraocular pressure, meeting individual target pressure goals (Early Manifest Glaucoma Trial, 2002).
• Slowing Disease Progression: Lowering pressure slows or halts progressive visual field loss and preserves optic nerve tissue.
• Reducing Medication Burden: Many patients achieve successful pressure control while reducing or eliminating daily hypotensive eye drops.
• 24-Hour Pressure Control: Surgical drainage provides continuous pressure reduction, minimizing diurnal spikes that accelerate nerve damage.

Recovery Timeline

Days 1 to 7: Mild discomfort, blurred vision, and redness are expected. Activity is restricted; heavy lifting, bending below the waist, and swimming are strictly prohibited. Topical antibiotic and steroid drops are taken daily.

Weeks 2 to 6: Vision gradually stabilizes as intraocular inflammation subsides. Postoperative adjustments, such as suture adjustments or laser suture lysis, may occur during weekly clinic visits.

Months 2 to 6: Steroid drops are slowly tapered under physician guidance. Final visual refraction and prescription glasses fitting typically occur around week 8 to 12 once the corneal shape stabilizes.

Indications and Conditions Treated

• Primary Open-Angle Glaucoma (POAG): Progressive optic nerve damage associated with open drainage angles and elevated pressure.
• Angle-Closure Glaucoma: Structural blockage of the trabecular meshwork by the iris, leading to acute or chronic pressure spikes.
• Normal-Tension Glaucoma: Optic nerve damage occurring despite intraocular pressure measuring in the statistically normal range.
• Secondary Glaucomas: Elevated pressure caused by pseudoexfoliation syndrome, pigment dispersion, inflammation (uveitis), trauma, or neovascularization.
• Congenital and Juvenile Glaucoma: Developmental defects in the eye's fluid drainage pathways present at birth or early childhood.

Preparation involves a full preoperative ocular examination including baseline intraocular pressure checks, corneal pachymetry, optical coherence tomography, and visual field mapping. Patients are instructed to continue prescribed glaucoma drops until the morning of surgery unless directed otherwise. Blood thinners may require temporary discontinuation under guidance from the managing primary physician. Patients must arrange transportation home on the day of surgery.

Complications vary by procedure type. Mild or temporary risks include transient early high pressure, transient low pressure (hypotony), minor hyphema (blood in the front chamber), and temporary blurry vision. Less common but serious risks include prolonged hypotony, choroidal detachment, shallow anterior chamber, early filtration flap failure due to scarring, and persistent hyphema. Rare severe risks include endophthalmitis (severe internal eye infection), suprachoroidal hemorrhage, total loss of vision, and bleb leaks requiring surgical repair.

Clinical Patient Journey

Pre-Surgical Workup: The journey begins with full ophthalmic testing. Clinicians measure intraocular pressure using goldmann applanation tonometry, map the visual field with perimetry, and evaluate optic nerve fiber layer thickness using optical coherence tomography (OCT). Anticoagulant regimens and topical eye drops are reviewed and adjusted prior to surgery.

Procedure Day: The patient receives local anesthesia with mild sedation in an outpatient surgical setting. Depending on whether trabeculectomy or a MIGS device is performed, surgical time ranges from 15 minutes to over an hour. A protective eye patch and shield are applied immediately afterward.

Postoperative Phase: Intensive monitoring occurs over the first four to eight weeks. Patients use topical corticosteroid and antibiotic eye drops. Post-trabeculectomy care may involve clinic visits for laser suture lysis or bleb needling to maintain optimal fluid outflow.

Long-Term Management: Periodic visual field testing, pressure monitoring, and optic nerve imaging continue indefinitely to ensure intraocular pressure remains within the safe target range.